Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Thursday, December 21st.
Several other equities research analysts have also recently weighed in on ACHN. Ladenburg Thalmann Financial Services cut their target price on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a research note on Tuesday, September 12th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Monday, November 6th. Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Robert W. Baird reiterated a “neutral” rating and issued a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Finally, Leerink Swann reiterated a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $5.13.
Achillion Pharmaceuticals (NASDAQ ACHN) traded down $0.01 during midday trading on Thursday, reaching $2.98. The company’s stock had a trading volume of 1,467,546 shares, compared to its average volume of 1,890,400. Achillion Pharmaceuticals has a 12-month low of $2.69 and a 12-month high of $5.66. The company has a market capitalization of $410.82, a PE ratio of -6.08 and a beta of 1.52.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. During the same period in the prior year, the firm earned ($0.15) EPS. research analysts predict that Achillion Pharmaceuticals will post -0.63 earnings per share for the current year.
In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.24% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in ACHN. RTW Investments LP raised its position in Achillion Pharmaceuticals by 392.9% during the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock worth $35,201,000 after purchasing an additional 6,249,312 shares during the last quarter. Janus Henderson Group PLC bought a new position in Achillion Pharmaceuticals during the 2nd quarter worth $20,778,000. Dimensional Fund Advisors LP raised its position in Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock worth $14,710,000 after purchasing an additional 1,407,108 shares during the last quarter. Sarissa Capital Management LP bought a new position in Achillion Pharmaceuticals during the 3rd quarter worth $9,594,000. Finally, FMR LLC raised its position in Achillion Pharmaceuticals by 11.0% during the 2nd quarter. FMR LLC now owns 1,603,622 shares of the biopharmaceutical company’s stock worth $7,361,000 after purchasing an additional 159,218 shares during the last quarter. Institutional investors own 76.92% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.